ESC 365 - Learnings from the latest PCSK9i results and and profiles of patients who may benefit the most: efficacy and safety of alirocumab in ODYSSEY OUTCOMES patients with diabetes

Open Access

Learnings from the latest PCSK9i results and and profiles of patients who may benefit the most: efficacy and safety of alirocumab in ODYSSEY OUTCOMES patients with diabetes

Session: Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data

Topic: Lipids

Speaker: Professor K. Ray (London, GB)

Sponsored by Sanofi and Regeneron

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)

91 presentations

16 followers

6 more presentations in this session

Welcome and introduction - Highlights from the latest ODYSSEY OUTCOMES data

Speaker: Professor A. Zeiher (Frankfurt, DE)

Learnings from the latest PCSK9i results and profiles of patients who may benefit the most: post- ACS patients with elevated atherogenic lipid levels

Speaker: Professor P. Steg (Paris, FR)

Learnings from the latest PCSK9i results and profiles of patients who may benefit the most: a comprehensive review of the latest lipid lowering therapies outcomes data

Speaker: Professor C. Cannon (Boston, US)

Clinical implications for post-ACS patients

Speaker: Doctor S. Goodman (Toronto, CA)

Roundtable: learnings in practice

Speaker: Professor P. Steg (Paris, FR) Professor A. Zeiher (Frankfurt, DE)

Access the full session

Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data

Speakers: Professor K. Ray, Professor A. Zeiher, Professor P. Steg, Professor C. Cannon, Doctor S. Goodman...

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources